利奈唑胺治疗耐多药结核病的初步评价

目的 初步评价利奈唑胺治疗耐多药结核（MDR-TB）的有效性与安全性。方法 检索Cochrane图书馆临床对照试验库、Pubmed、Embase、CBM、CNKI、Wanfang Date等电子数据库。对符合纳入标准的临床研究进行统计分析。结果 共有７个国家的5个临床研究符合纳入标准。分析结果表明，含利奈唑胺的联合化疗方案治疗MDR-TB的合并成功率为82%（95%CI 73%～89%）；治疗结果为失败、丢失或死亡的比例分别为2%、5%、11%。血液系统不良反应、神经毒性和胃肠道反应的发生率分别为32%、25%、6%。结论 利奈唑胺对耐多药结核病有较好的疗效，但药物不良反应发生率较高。

Treatment outcomes of linezolid for multidrug-resistant tuberculosis:a systematic review and meta-analysis

Objective To evaluate the efficacy and safety of linezolid for treating multidrug resistant tuberculosis（MDR-TB）. Methods Cochrane Controlled Trials database,Pubmed,Embase,CBM,CNKI,Wanfang Date and other electronic databases were searched.Clinical studies matched the inclusion criteria would be analysed statistically. Results A total of five clinical studies met the inclusion criteria in seven countries.The results showed that the mean proportion of patients achieving treatment success was 82%（95% CI 73%-89%）;the mean proportion of patients whose outcome were treatment failure,default and death were 2%,5% and 11%,respectively.The incidence rate of adverse events in hematopoietic system and neurotoxicity and gastrointestinal system were 32%,25%,6%,respectively. Conclusion Linezolid against MDR-TB has a good efficacy,but the incidence of adverse events is higher.